Investor Relations

News Releases

<< Back
May 07, 2020
Intersect ENT to Present at the 2020 Bank of America Merrill Lynch Global Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--May 7, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), today announced that management will participate in a virtual fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference. The fireside chat will take place on Thursday, May 14, 2020 at 2:20 p.m. EDT.

To access the webcast, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. The webcast replay will be archived for approximately one month.

About Intersect ENT®

Intersect ENT is a company transforming care for patients with ear, nose and throat conditions. The Company’s steroid-releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL® (mometasone furoate) sinus implants and SINUVA® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.

Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of Intersect ENT, Inc.

XENT-F

Inquiries:
Intersect ENT, Inc.
Richard Meier
650.641.2105
ir@intersectENT.com

Source: Intersect ENT, Inc.